Should I buy Danaher Corporation (DHR) stock or is it too late?

Danaher Corporation · Health Care · price $216

See the full Danaher Corporation (DHR) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stifel — 68% of its targets hit on this sector (299 calls tested). It aims for $220 (+2.0 %), call made on July 23, 2026, maturing on July 23, 2027 (36 d ago).

The 5 reliable analysts $200-7.3 %

The 9 other firms $230+6.6 %

How to read it: the 5 reliable firms are not filtered by optimism — 2 aim above the price, 3 below, hence their $200 median. “The 9 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Danaher Corporation

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
B of A Securities	80 %	+31.5 %	5	$220 +2%
Citigroup	82 %	+26.7 %	17	$95 -56%
Morgan Stanley	100 %	+26.0 %	12	$255 +18%
Wells Fargo	75 %	+23.9 %	8	$195 -10%
Jefferies	75 %	+18.1 %	8	$265 +23%
JP Morgan	70 %	+12.4 %	10	$275 +28%
Stifel	80 %	+10.4 %	5	$220 +2%
UBS	44 %	+10.1 %	9	$250 +16%

In short — Should you invest in Danaher Corporation? Is it too late, still worth it? Analysts are fairly positive (79% buy, median target $230, i.e. +7%), and the most reliable on DHR targets even higher. But the valuation is stretched (P/E ~38). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

79% of analysts rate it a buy (Buy consensus, 14 ratings) — a sign of market conviction.
The most reliable firm on DHR, Morgan Stanley (100% hit rate, 12 scored calls), targets $255 (call made on April 23, 2026, maturing on April 23, 2027) (+18%) in its most recent call, and $270 (call made on December 2, 2025, maturing on December 2, 2026) (+25%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 14 ratings, 3 are neutral.
Limited upside: the median target is only +7% from the current price.
High valuation (P/E ~38): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on DHR

Median target $230 (+7%) · 14 ratings · Buy consensus

Strong Buy00%

Buy1179%

Hold321%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Danaher Corporation now?

We won't decide for you. The facts: 79% of analysts rate it a buy, median target $230 (+7%), and Morgan Stanley (most reliable on DHR, 100%) targets $255. Weigh that against valuation (P/E ~38). This is not personalized advice.

Is it too late to invest in Danaher Corporation?

Not according to analysts: the median target ($230) is still +7% above the current price ($216) (most reliable on DHR: Morgan Stanley, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Danaher Corporation still worth investing in?

It depends on the gap between the price ($216) and its estimated value: analysts target $230 on median (+7%), with 79% buys (most reliable on DHR: Morgan Stanley, 100%). Cross-check with their real reliability on DHR and the cautions above. Information, not advice.

What's the main risk in buying DHR?

The consensus is not unanimous: of 14 ratings, 3 are neutral.

→ Go deeper: the full Danaher Corporation profile (consensus, analyst reliability, price target, performance).